Year Established: 1986
Net Income: $5,455
*Celgene figures are estimates for Jan 2019-Nov 2019, as they were acquired by BMS prior to the end of the year.
TOP SELLING DRUGS
|Revlimid||multiple myeloma, mantle cell lymphoma||$9,671||0%|
|Abraxane||breast, lung, pancreatic cancer||$1,087||2%|
|Idhifa||Leukaemia, acute myeloid||$98||36%|
|Thalomid||leprosy, multiple myeloma||$82||-28%|
Celgene became a wholly owned subsidiary of Bristol-Myers Squibb following the completion of the $74 billion acquisition in November. The merger creates a leading oncology franchise in both solid tumors and hematologic malignancies with Opdivo and Yervoy as well as Revlimid and Pomalyst; a top five immunology and inflammation franchise with Orencia and Otezla; and the number one cardiovascular franchise led by Eliquis. The combined company, which has nine products with more than $1 billion in annual sales, will likely rank #5 or #6 in next year’s report.
In connection with the merger with BMS, Celgene entered an agreement to sell the global rights to one of its top sellers OTEZLA to Amgen for $13.4 billion. Otezla is currently approved for three indications in the U.S., moderate-to-severe plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's Disease. Otezla is approved in more than 50 markets outside the U.S., including the EU and Japan, and has patent exclusivity through at least 2028 in the U.S., and will remain a key competitor in the psoriasis market.
Since the merger was announced back in January of 2019, there have been several advancements of key value drivers, namely patent progress for top seller REVLIMID, the FDA approvals of INREBIC (fedratinib) for certain forms of myelofibrosis, and REBLOZYL for Thalassaemia, along with regulatory filings of luspatercept and ozanimod in the U.S. and Europe.
REBLOZYL, for the treatment of anemia in patients with beta thalassemia who require regular red blood cell transfusions, is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy which works by regulating late-stage red blood cell maturation to help patients reduce their RBC transfusion burden.
Also, the FDA approval of INREBIC (Fedratinib) represents the first new treatment in nearly a decade for patients with Myelofibrosis, providing a once-daily oral option for patients affected by the rare bone marrow cancer.
Among other advancing assets, Celgene’s Phase III QUAZAR AML-001 Study of CC-486 as maintenance therapy in newly diagnosed Acute Myeloid Leukemia met primary and key secondary endpoints, with analysis showing a highly statistically significant and clinically meaningful improvement in overall survival. Celgene plans regulatory submissions beginning 1H20.
Lastly, as part an effort to advance cell manufacturing, Celgene and Ovizio Imaging Systems executed supply agreements for the automation of certain engineered T cell manufacturing processes. Celgene will be using Ovizio's on-line iLine F microscope, and the BioConnect system, a closed, single-use fluidic sampling system, to further automate the manufacturing of engineered T-cell investigational products and improve product control across its global manufacturing network.